These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

729 related items for PubMed ID: 34309862

  • 1. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 2. Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study.
    Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F.
    Headache; 2021 Feb; 61(2):363-372. PubMed ID: 33337544
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
    Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group.
    J Headache Pain; 2021 May 03; 22(1):35. PubMed ID: 33941080
    [Abstract] [Full Text] [Related]

  • 5. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).
    Barbanti P, Egeo G, Aurilia C, d'Onofrio F, Albanese M, Cetta I, Di Fiore P, Zucco M, Filippi M, Bono F, Altamura C, Proietti S, Bonassi S, Vernieri F, FRIEND-Study Group.
    J Headache Pain; 2022 Apr 09; 23(1):46. PubMed ID: 35397503
    [Abstract] [Full Text] [Related]

  • 6. Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study.
    Barbanti P, Egeo G, Proietti S, d'Onofrio F, Aurilia C, Finocchi C, Di Clemente L, Zucco M, Doretti A, Messina S, Autunno M, Ranieri A, Carnevale A, Colombo B, Filippi M, Tasillo M, Rinalduzzi S, Querzani P, Sette G, Forino L, Zoroddu F, Robotti M, Valenza A, Camarda C, Borrello L, Aguggia M, Viticchi G, Tomino C, Fiorentini G, Orlando B, Bonassi S, Torelli P, Italian Migraine Registry study group.
    Neurol Ther; 2024 Jun 09; 13(3):611-624. PubMed ID: 38451463
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
    Reuter U, Goadsby PJ, Ferrari MD, Da Silva Lima GP, Mondal S, Kalim J, Hasan F, Wen S, Arkuszewski M, Pandhi S, Stites T, Lanteri-Minet M.
    Neurology; 2024 May 09; 102(10):e209349. PubMed ID: 38669638
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Assessment of prolonged safety and tolerability of erenumab in migraine patients in a long-term open-label study (APOLLON).
    Göbel H, Schlegel E, Jaeger K, Ortler S, Leist L.
    J Headache Pain; 2024 Sep 25; 25(1):157. PubMed ID: 39322961
    [Abstract] [Full Text] [Related]

  • 10. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
    De Icco R, Vaghi G, Allena M, Ghiotto N, Guaschino E, Martinelli D, Ahmad L, Corrado M, Bighiani F, Tanganelli F, Bottiroli S, Cammarota F, Sances G, Tassorelli C.
    J Headache Pain; 2022 Sep 17; 23(1):123. PubMed ID: 36115947
    [Abstract] [Full Text] [Related]

  • 11. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy.
    Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA, Assetta M, Maddestra M, Marzoli F, Viola S, Cerone D, Marini C, Pistoia F, Sacco S.
    J Headache Pain; 2020 Apr 07; 21(1):32. PubMed ID: 32264820
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
    Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD.
    Headache; 2022 May 07; 62(5):624-633. PubMed ID: 35593783
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2.
    Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R.
    Headache; 2021 Jan 07; 61(1):125-136. PubMed ID: 33314079
    [Abstract] [Full Text] [Related]

  • 14. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study.
    Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA.
    Neurology; 2017 Sep 19; 89(12):1237-1243. PubMed ID: 28835404
    [Abstract] [Full Text] [Related]

  • 15. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
    Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ.
    Headache; 2020 Oct 19; 60(9):2014-2025. PubMed ID: 32920850
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J.
    Lancet; 2018 Nov 24; 392(10161):2280-2287. PubMed ID: 30360965
    [Abstract] [Full Text] [Related]

  • 17. [The efficacy and safety of Erenumab in patients with high-frequency episodic migraine according to the first Russian real-life study of the Research Center of Neurology].
    Dobrynina LA, Gubanova MV, Belopasova AV, Baydina EV, Afanasev MA.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 Nov 24; 122(2):74-80. PubMed ID: 35271240
    [Abstract] [Full Text] [Related]

  • 18. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.
    Headache; 2021 Jun 24; 61(6):927-935. PubMed ID: 34153117
    [Abstract] [Full Text] [Related]

  • 19. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A.
    BMC Neurol; 2022 Jun 16; 22(1):221. PubMed ID: 35710354
    [Abstract] [Full Text] [Related]

  • 20. Timing and durability of response to erenumab in patients with chronic migraine.
    Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J, Klatt J, Chou DE, Wang A, Paiva da Silva Lima G.
    Headache; 2021 Sep 16; 61(8):1255-1263. PubMed ID: 34363708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.